Skip to main content
HERON THERAPEUTICS, INC. /DE/ logo

HERON THERAPEUTICS, INC. /DE/ — Investor Relations & Filings

Ticker · HRTX ISIN · US4277461020 LEI · 549300DR2I1DOPD2IX53 US Manufacturing
Open in API
Filings indexed 1,030 across all filing types
Latest filing 2025-10-18 Director's Dealing
Country US United States of America
Listing US HRTX

About HERON THERAPEUTICS, INC. /DE/

https://www.herontx.com/

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and commercializing therapies to address unmet medical needs in acute care and oncology. The company utilizes its proprietary drug delivery technologies to create novel, best-in-class treatments. Its product portfolio is designed to improve the lives of patients by providing solutions for significant medical issues, including postoperative pain management, with an aim to reduce opioid reliance, as well as managing postoperative and chemotherapy-induced nausea and vomiting.

Recent filings

Filing Released Lang Actions
Director's Dealing 2025
Director's Dealing
2025-10-18 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated October 15, 2025, reporting on the results of a Special Stockholders' Meeting held on October 13, 2025. The key content is the submission of matters to a vote of security holders, detailing the voting results on two proposals related to the issuance of shares pursuant to Nasdaq Listing Rule 5635(d). The document includes vote counts and confirms the quorum. There are no financial statements or detailed financial data presented, only the voting results. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document is not an Annual Report, Earnings Release, or any other report type, but specifically reports official shareholder vote results. The length (5903 characters) and content confirm it is not merely an announcement of a report but the actual voting results filing.
2025-10-15 English
DEF 14A
Proxy Solicitation & Information Statement
2025-09-19 English
Regulatory Filings 2025
Regulatory Filings
2025-09-17 English
Regulatory Filings 2025
Regulatory Filings
2025-09-17 English
Capital/Financing Update 2025
Capital/Financing Update Classification · 95% confidence The document is a correspondence letter addressed to the SEC regarding a Registration Statement on Form S-3. It requests acceleration of the effective date of the registration statement under Rule 461 of the Securities Act of 1933. The content is a formal communication about a capital markets filing, specifically related to securities registration and offering. It does not contain financial statements, audit information, or detailed report content. It is not a report itself but an update or regulatory communication about a financing registration. Therefore, it fits best under Capital/Financing Update (CAP). The document length is short and focused on a financing regulatory matter, confirming the classification.
2025-09-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.